Given 2 Years, Living 13 Strong
Living 13 Years Strong: Debbie’s Stage 4 Lung Cancer Journey of Hope and Persistence
When Debbie was first diagnosed with stage 4 lung cancer, doctors told her she might only have one to two years left. Like many patients, she felt overwhelmed and afraid. But instead of giving up, she sought a second opinion and learned that her cancer carried the BRAF mutation. This discovery opened the door to targeted therapy through a clinical trial—something that gave her options beyond traditional chemotherapy and radiation.
Over the last 13 years, Debbie has faced many treatments, side effects, and setbacks, but also many breaks from therapy where she could live life more fully. She has outlived the predictions and now encourages other patients to stay hopeful, ask questions, and keep pushing for answers. Debbie’s story shows how advances in biomarker testing and targeted therapy can turn what once felt like an “end date” into years filled with milestones and new memories.
Her journey reminds us that no one is defined by statistics. For patients with advanced lung cancer, Debbie is living proof that hope, persistence, and medical progress can lead to more time and better quality of life. (Source: GO2 for Lung Cancer)
Safer Cancer Drug Dosing Ahead
Safer Cancer Drug Dosing: ASCO and FDA Push for Optimal, Not Maximum, Doses
Concerns are growing that cancer drugs may be given at higher doses than patients actually need, leading to unnecessary side effects and treatment interruptions. The American Society of Clinical Oncology (ASCO), working with the FDA, has issued new principles urging a shift from the old “maximum tolerated dose” approach toward finding the “optimal effective dose.” This matters for newer treatments like immunotherapies and targeted therapies, where higher doses don’t always improve results but often increase harmful side effects. Patient surveys show many people with advanced cancers struggle with severe treatment side effects, and oncologists frequently lower doses early on to help patients stay on therapy.
To fix this, ASCO recommends designing trials that test multiple dosage levels, tailoring studies to real-world patients, and improving how patient-reported side effects are tracked. These steps align with the FDA’s Project Optimus, which is pushing for better drug dosing in cancer research. For patients, this shift offers hope for treatment that works just as well—or better—while being easier to tolerate, helping people with advanced cancer focus on living fully instead of fighting side effects. (Source: Oncology News Central)
Read the complete article here >
New Clues on How Cancer Spreads
New Clues on Cancer Metastasis: How “Shape-Shifting” Cells Spread and Survive
For decades, doctors have known that cancer’s deadliest threat comes not from the original tumor but from metastasis — when cancer spreads to other parts of the body. Up to 90% of cancer deaths are linked to this process. Now, researchers led by Dr. Joan Massagué at Memorial Sloan Kettering are uncovering important insights into how metastatic cells survive, hide, and return to grow new tumors years later. These “shape-shifting” cells act like stem cells, traveling back in time to earlier, more flexible states that allow them to adapt and resist treatment. They can also slip into dormancy, hiding from the immune system until the conditions are right to awaken and spread again.
Scientists are learning that metastatic cells use different strategies depending on the type of cancer and the organ they invade. They can even change their physical shape to avoid being destroyed by the immune system. These discoveries open new possibilities for treatment — from targeting the hidden “time traveler” state, to waking dormant cells so the immune system can attack them, to blocking proteins that allow cancer cells to evade detection. While challenges remain, Dr. Massagué emphasizes that metastasis is no longer an automatic death sentence. With advances in immunotherapy and targeted research, controlling — and in some cases curing — stage 4 cancer is becoming more possible than ever before. (Source: Memorial Sloan Kettering)
Future of Cancer Screening Shows Hope
Future of Cancer Screening: Multi-Cancer Early Detection Brings New Hope
Most cancers are still found late because only five types—colon, cervical, breast, lung, and prostate—have routine screening. A new direction called multi-cancer early detection (MCED) aims to spot cancers with a single test. Instead of hunting for tiny, hard-to-find tumor DNA fragments in the blood, researchers are building tiny “sensors” that circulate in the body and switch on when they meet enzymes made by early cancer cells. These sensors release a synthetic marker that shows up clearly in samples like urine, creating a much stronger, earlier signal than traditional tests in preclinical studies.
Why it matters: this approach could make screening simpler, more accurate, and more accessible—potentially even via low-cost strips for clinics with limited resources—and may help catch hard-to-find cancers (including lung cancer) sooner, when treatment works best. Logic-based sensor designs (think an “AND” gate requiring multiple cancer signals) may reduce false alarms, and early clinical use could include tracking treatment response or watching for recurrence. Safety testing is still ahead, but progress is rapid. If successful, MCED could shift many diagnoses from late-stage to early-stage—and offer hope and options for people living with or at risk for advanced disease. (Source: MIT Technology Review)
Read the complete article here >
Living Fully: Joanne’s Cancer Journey
Living Fully with Non-Small Cell Lung Cancer: Joanne’s Story of Hope and Healing
When Joanne was diagnosed with non-small cell lung cancer in 2021, she couldn’t help but ask the same question many patients face: “Why me?” She had lived a healthy lifestyle, exercised, and avoided processed foods, yet found herself retracing her past for answers—secondhand smoke in childhood, brief years of social smoking, exposure to environmental toxins, stress, or perhaps random chance. Her pathology revealed an EGFR mutation, a genetic change often seen in people with little or no smoking history, which allowed her to begin targeted therapy after surgery and chemotherapy.
Over time, Joanne realized that focusing on blame only robs her of peace. Instead, she has chosen to center her life around gratitude, faith, and the love of her husband and community. With new advances in treatment, she believes lung cancer should no longer be viewed as an automatic death sentence or a punishment tied to smoking. Through sharing her story, Joanne hopes to break the stigma, reminding us that compassion and understanding—not judgment—are what every patient deserves. (Source: Joanne Gaget Blog)
Yoga, Meditation, and More Bring Relief
Yoga, Meditation, and Integrative Medicine Ease Cancer Treatment Side Effects
A new clinical trial shows that live, online classes in yoga, meditation, tai chi, and fitness can do more than just help patients feel calmer — they can actually reduce the side effects of cancer treatment. Patients who joined these virtual integrative medicine sessions during chemotherapy, radiation, immunotherapy, or targeted therapy reported less fatigue, anxiety, depression, and trouble sleeping. Remarkably, they also needed fewer hospital stays, and when they were admitted, their time in the hospital was much shorter.
This approach, offered through Memorial Sloan Kettering’s Integrative Medicine at Home program, costs $25 per month and is available to patients anywhere — not just those treated at MSK. Many patients find the classes give them both physical strength and emotional support by connecting with others going through cancer. Other services like acupuncture and music therapy can also play a role in making treatment more tolerable. Research continues to grow, with hopes of expanding access nationwide. For patients and caregivers, these integrative therapies provide a safe, evidence-based way to feel stronger and more supported throughout cancer treatment. (Source: Memorial Sloan Kettering)
Riding Through Cancer: Christy’s Story
Riding My Harley Through Cancer: Christy’s Stage 4 Lung Cancer Story
When Christy Erickson was diagnosed with stage IV lung cancer at just 41, she feared she wouldn’t see her children grow up. But after months of unanswered questions and second opinions, genetic testing revealed her tumor carried an EGFR mutation—opening the door to a targeted therapy called osimertinib. This treatment, born from years of research, gave her what once seemed impossible: more time with her family and the chance to live fully, not just survive.
Christy has faced her journey with courage, faith, and determination. She’s checked off bucket-list dreams, from riding her own Harley to competing in strongman events, and she shares her story to encourage others to advocate for themselves. “Osimertinib gave me time,” she says—time to see her daughter graduate, time to rediscover joy, and time to inspire other patients that even after a stage IV diagnosis, hope and healing are possible. (Source: Winship Cancer Institute of Emory University)
Second Opinions Can Save Lives
Why Getting a Second Opinion for Cancer Can Save Your Life
Being told you have cancer is overwhelming, and it’s easy to feel pressured to start treatment right away. But getting a second opinion can make a huge difference—it may confirm the diagnosis, catch mistakes, or suggest new treatment options. For patients with stage 4 or hard-to-treat lung cancer, this extra step can open the door to advanced therapies and clinical trials not available everywhere.
Specialists at National Cancer Institute-designated centers look deeper than a single test. They review scans, biopsy slides, and genetic testing to match you with the best targeted therapy or immunotherapy. Many doctors welcome second opinions, and sometimes both teams can work together—giving you more support, not less.
Most importantly, a second opinion can give you peace of mind. Knowing your diagnosis and plan have been double-checked helps you move forward with confidence and focus on what matters most: your care and your life. (Source: Winship Magazine)
Read the complete article here >
What’s Driving Lung Cancer in Nonsmokers?
What’s Driving Lung Cancer in Nonsmokers? Understanding RET-Positive Lung Cancer
Lung cancer isn’t just a smoker’s disease. In fact, up to 20% of lung cancer patients have never smoked, and many are younger women. One reason? Genetic mutations like RET fusions, which can drive cancer growth even without traditional risk factors. This type, called RET-positive lung cancer, is more common in never smokers and doesn’t show up on routine screenings.
That’s why genetic testing (also called biomarker testing) is critical. It can help doctors choose targeted treatments that work better and offer more hope—especially for patients with stage 4 or hard-to-treat lung cancer. Even if you’ve never smoked, if you’re experiencing unusual symptoms or have lung cancer in your family, talk to your doctor about testing. Early detection and personalized care are changing what’s possible. (Source: American Cancer Society, Yale Medicine, J Clin Oncol)











